April 2021
The Institute of Biomedical Science (IBMS) pays tribute to the biomedical scientists and laboratory staff who have made, and will continue to make, a vital contribution in tackling COVID-19 while maintaining high-quality healthcare services:
A run-down of clinical trials news for the week ending 2nd April, courtesy of BioSpace.com:
A team of researchers from Stanford University working with biotechnology corporation Genentech, has developed an artificial-intelligence based system that can safely add clinical trial participants that may have previously been excluded:
The eClinical & Clinical Data Management Innovation Conference 2021 will be held online on 2nd June. It is free to Pharma, Biotech and Medical Devices companies and all attendees will receive a free copy of ‘The Covid-19 Pandemic Impact on Clinical Trials’ report:
By deploying surface testing, the Eurofins Steins Laboratory in Vejen, Denmark, was able to detect the presence of SARS-CoV-2 one week before infected occupants even experienced symptoms, ensuring no interruption to operations:
internationalairportreview.com
The Outsourcing in Clinical Trials Europe 2021 conference will take place online on Wednesday 5th and Thursday 6th May. It is free to Pharma, Biotech and Medical Devices companies and offers a free Clinical Trial Assessment and a free copy of ‘State of the Biopharmaceutical Industry 2021’ report:
The Pistoia Alliance, a global, not-for-profit alliance advocating for greater collaboration in life sciences R&D, has launched its Data Governance Community of Interest (CoI) to develop best practices and advance digital transformation in the pharma/life sciences industry:
europeanpharmaceuticalreview.com
An artificial-intelligence tool called Trial Pathfinder can run clinical-trial emulations using health-care data from people with cancer, and can learn how to optimize trial-inclusion eligibility criteria, while maintaining patient safety:
The LIMS market is expected to grow at a CAGR of around 12% during the period 2020−2026 from $1.1bn to over $2bn according to the latest report from Arizton Advisory and Intelligence:
Sharp declines in US biotech stock indices gave equity investors a nervous start to 2021, but start-up drug developers raised a phenomenal $7.1bn in venture cash:
American coronavirus tracking can't keep up with concerning variants. The USA has an enormous virus-sequencing capacity, but funding and coordination roadblocks are holding it back:
Important material on the six key areas where the UK must increase research scale to maintain resilience against Covid-19 - the National Core Studies:
Of these, the Clinical Trials Infrastructure programme builds on established National Institute for Health Research (NIHR) infrastructure (and equivalent in Devolved Administrations) to accelerate delivery of large scale Covid trials for drugs and vaccines:
